Literature DB >> 3001926

Liver disease in alpha 1-antitrypsin deficiency. Aspects of incidence and prognosis.

S G Eriksson.   

Abstract

Entities:  

Mesh：

Year:  1985        PMID： 3001926     DOI： 10.3109/00365528509088844

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN： 0036-5521            Impact factor:   2.423


× No keyword cloud information.
  9 in total

Review 1.  The epidemiology of alpha 1-antitrypsin deficiency.

Authors:  D C Hutchison
Journal:  Lung       Date:  1990       Impact factor: 2.584

Review 2.  Diagnosis and management of patients with α1-antitrypsin (A1AT) deficiency.

Authors:  David R Nelson; Jeffrey Teckman; Adrian M Di Bisceglie; David A Brenner
Journal:  Clin Gastroenterol Hepatol       Date:  2011-12-23       Impact factor: 11.382

3.  Characteristics of hepatocellular carcinoma in a murine model of alpha-1-antitrypsin deficiency.

Authors:  Nancy Y Marcus; Elizabeth M Brunt; Keith Blomenkamp; Faiza Ali; David A Rudnick; Muneeb Ahmad; Jeffrey H Teckman
Journal:  Hepatol Res       Date:  2010-06       Impact factor: 4.288

4.  Alpha-1 antitrypsin deficiency and the risk of hepatocellular carcinoma in end-stage liver disease.

Authors:  Clara Antoury; Rocio Lopez; Nizar Zein; James K Stoller; Naim Alkhouri
Journal:  World J Hepatol       Date:  2015-06-08

5.  An association between alpha 1-antitrypsin phenotype and chronic liver disease.

Authors:  Y Kishimoto; S Yamada; C Hirayama
Journal:  Hum Genet       Date:  1990-01       Impact factor: 4.132

6.  Late manifestation of chronic liver disease in adults with alpha-1-antitrypsin deficiency.

Authors:  J Rakela; M Goldschmiedt; J Ludwig
Journal:  Dig Dis Sci       Date:  1987-12       Impact factor: 3.199

7.  Alpha 1-antitrypsin and survival in hepatocellular carcinoma.

Authors:  A Tzonou; L Sparos; V Kalapothaki; X Zavitsanos; A Rebelakos; D Trichopoulos
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640

8.  Activation of the c-Jun N-terminal kinase pathway aggravates proteotoxicity of hepatic mutant Z alpha1-antitrypsin.

Authors:  Nunzia Pastore; Sergio Attanasio; Barbara Granese; Raffaele Castello; Jeffrey Teckman; Andrew A Wilson; Andrea Ballabio; Nicola Brunetti-Pierri
Journal:  Hepatology       Date:  2017-04-10       Impact factor: 17.425

Review 9.  Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges.

Authors:  Shen Li; Antonio Saviano; Derek J Erstad; Yujin Hoshida; Bryan C Fuchs; Thomas Baumert; Kenneth K Tanabe
Journal:  J Clin Med       Date:  2020-11-25       Impact factor: 4.241
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.